eligibility_summary
Eligible: adults 18–70 with newly diagnosed double-expressor DLBCL, ECOG 0–2, Ann Arbor stage II–IV, life expectancy ≥3 months, and meeting trial lab criteria. Exclude: CNS involvement, uncontrolled cardiovascular/cerebrovascular disease, coagulopathy, or connective tissue disease, uncontrolled infections (HBV/HCV/HIV), candidates for transplantation, pregnant or breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in treatment-naïve double-expression DLBCL testing orelabrutinib plus R-CHOP. Orelabrutinib: covalent Bruton’s tyrosine kinase (BTK) inhibitor (small-molecule) that blocks B-cell receptor signaling, suppressing survival/proliferation of malignant B cells. R-CHOP components and mechanisms: rituximab (anti-CD20 monoclonal antibody, depletes CD20+ B cells via ADCC/CDC and apoptosis), cyclophosphamide (alkylating agent, DNA crosslinks), doxorubicin/epirubicin/liposomal doxorubicin (anthracycline, DNA intercalation, topoisomerase II inhibition, ROS), vincristine/vindesine (vinca alkaloid, microtubule inhibitor, mitotic arrest), prednisone (corticosteroid, lymphocyte apoptosis). Cells/pathways targeted: CD20+ malignant B cells, BTK/BCR signaling, DNA replication/repair, microtubules, immune effector mechanisms. Primary endpoint: complete response rate after induction.